Purpose of study
The aim of the trial is try to improve the way PET-CT scans show how well chemotherapy is working.
When you have a PET-CT scan, you have a drug called a ‘tracer’ first. A tracer is picked up by body cells and shows up on the scan.
Doctors choose the tracer for a PET scan depending on what they are looking for. The researchers think that isatin sulfonamide is picked up by dying cancer cells. If this is correct, a PET-CT scan using this tracer will help doctors to tell how well chemotherapy is working.
What is involved
There is no treatment in this study but to enter, you must be about to have chemotherapy for your lymphoma. When you join the trial, you first have a screening visit. The trial doctor asks how you are, takes your medical history and then examines you. If the screening is satisfactory, you can join the trial.
You have 2 PET-CT scans as part of the trial: 1 before and 1 during your chemotherapy treatment. Before each scan, you have the scan tracer isatin sulfonamide intravenously (through a drip into a vein). You also give some blood samples.
Each scan takes just over an hour. You have to keep very still during this time but you can listen to music.
Who can enter
Your consultant can give you advice on whether this study might be suitable for you.
Around 20 people are needed for this trial
You may be able to enter if:
- You have any type of lymphoma.
- At least one area of lymphoma measures 1.5cm or more on a scan.
- You are about to start chemotherapy as treatment for your lymphoma.
- You are well enough to look after yourself and are up and about more than 50% of your waking hours, even if you are not well enough to work.
- You and your partner are willing to use reliable contraception if there is any chance of you or your partner becoming pregnant.
- Your blood and other health test results are satisfactory.
- You are at least 18.
You will not be able to enter if:
- You’ve had any cancer drug treatment in the 2 weeks before your first PET-CT scan.
- You are pregnant or breastfeeding.
- You are monitored at work for exposure to radiation.
More information about this trial is available at Cancer Research UK.